Dr. Blue on the Utility of Carfilzomib in Relapsed/Refractory Multiple Myeloma

Brandon Blue, MD, discusses the utility of carfilzomib in relapsed/refractory multiple myeloma.

Brandon Blue, MD, oncologist, Malignant Hematology, Health Outcomes and Behavior Program, Moffitt Cancer Center, discusses the utility of carfilzomib (Kyprolis) in relapsed/refractory multiple myeloma.

Bortezomib (Velcade) and carfilzomib should be considered for patients who are sensitive to proteasome inhibitors (PI), Blue explains. If a patient has a good response with frontline bortezomib, using carfilzomib, a second-generation PI, could be used. Carfilzomib can be used in combination with multiple agents, including daratumumab (Darzalex), isatuximab-irfc (Sarclisa), and pomalidomide (Pomalyst), Blue says.

Several options can be utilized to capitalize on the mechanism of action associated with PIs, Blue continues. Moreover, PIs have demonstrated a progression-free survival advantage, as well as increased rates of minimal residual negativity, which is associated with improved outcomes for patients, Blue concludes.